Journals / Nöropsikiyatri Arşivi / 2022 / Cilt: 59 - Sayı: 2

Prevalence and Clinical Features of Idiopathic Parkinson’s Disease in Western Turkey

Batı Türkiye’de İdiyopatik Parkinson Hastalığının Prevalansı ve Klinik Özellikleri

Pages
98–104
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusions: IPD prevalence studies will increase the awareness in the community and provide early diagnosis and treatment as well as serve as a basis to increased life expectancy, reduce morbidity, and improve life quality.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: We aimed to determine the prevalence and risk factors of idiopathic Parkinson’s disease (IPD) in Western Turkey, which encompasses Edirne and its surrounding districts.
📊
Key Findings & Data:Methods: In this study, 9887 individuals, able to communicate and agreed to participate in the study, were evaluated.
💡
Conclusion & Impact:Conclusions: IPD prevalence studies will increase the awareness in the community and provide early diagnosis and treatment as well as serve as a basis to increased life expectancy, reduce morbidity, and improve life quality.
🔬Design:Survey & Empirical Study
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Introduction: We aimed to determine the prevalence and risk factors of idiopathic Parkinson’s disease (IPD) in Western Turkey, which encompasses Edirne and its surrounding districts. Methods: In this study, 9887 individuals, able to communicate and agreed to participate in the study, were evaluated. The data was obtained by answering a face-to-face questionnaire consisting of 53 questions from volunteers living at 30 randomly selected family health centers in Edirne and its counties. The questionnaire included demographic information, questions to evaluate potential concomitant conditions, and questions regarding the symptomatology used in IPD diagnosis. Following the questionnaire, it was planned to determine the degree of IPD with the Unified Parkinson’s Disease Rating Scale (UPDRS) and the Hoehn and Yahr scale (HY) clinical rating scale in patients diagnosed with IPD to assess disease severity in patients diagnosed with IPD Results: Of the 9887 individuals, 118 were diagnosed with IPD according to the questionnaire results from Edirne and its districts, and the prevalence of IPD was 1.2%. Approximately, 58.4% of the patients with IPD were male and 41.6% were female, which was not significantly different (p=0.214). Non-motor symptoms such as difficulty urinating, anxiety, depression, fatigue, REM sleep behavior disorder, and difficulty falling asleep or staying asleep were also examined in patients diagnosed with IPD. Depression was identified in 45.7% of the cases, while the control group was 4.3% (p=0.001). Fatigue was identified in 46.8% of the cases and control group was 3.5% (p=0.002). Conclusions: IPD prevalence studies will increase the awareness in the community and provide early diagnosis and treatment as well as serve as a basis to increased life expectancy, reduce morbidity, and improve life quality.

Özet

Amaç: Edirne ve çevresini kapsayan Türkiye’nin batı bölgesindeki İdiyopatik Parkinson Hastalığının (İPH) prevalansını ve risk faktörlerini belirlemeyi amaçladık. Yöntem: Bu çalışmada iletişim kurabilen ve çalışmaya katılmayı kabul eden 9887 kişi değerlendirildi. Veriler, Edirne ve ilçelerinde rastgele seçilen 30 aile sağlığı merkezinde yaşayan gönüllülerden 53 sorudan oluşan yüz yüze ankete cevap verilerek elde edildi. Anket demografik bilgileri, olası eşlik eden durumları değerlendirmeye yönelik soruları ve İPH tanısında kullanılan semptomatolojiye ilişkin soruları içeriyordu. Anketin ardından İPH tanısı alan hastalarda hastalık şiddetini değerlendirmek için Birleşik Parkinson Hastalığı Değerlendirme Ölçeği (UPDRS) ve Hoehn ve Yahr ölçeği (HY) klinik derecelendirme ölçeği ile IPH derecesinin belirlenmesi planlandı. Bulgular: Edirne ve ilçelerinden elde edilen anket sonuçlarına göre 9887 kişiden 118’ine İPH tanısı kondu ve İPH prevalansı %1,2 idi. İPH’li hastaların yaklaşık %58,4’ü erkek, %41,6’sı kadındı ve cinsiyetler arasında istatistiksel olarak anlamlı bir fark yoktu. (p=0,214). İPH tanısı alan hastalarda idrar yapma güçlüğü, anksiyete, depresyon, yorgunluk, REM uyku davranış bozukluğu, uykuya dalma veya uykuda kalma gibi nonmotor belirtiler de incelendi. Olguların %45,7’sinde, kontrol grubunda ise %4,3’ünde depresyon tespit edildi (p=0,001). Olguların %46,8’in de ve kontrol grubunda ise %3,5’inde yorgunluk belirlendi (p=0,002). Sonuç: İPH prevalans çalışmaları toplumda farkındalığı artıracak, erken tanı ve tedaviyi sağlayacak, yaşam beklentisinin artması, morbiditenin azaltılması ve yaşam kalitesinin iyileştirilmesi için bir temel oluşturacaktır

🔖

Cite This Article

TURAN, F. N., CAYLAN, A., DAĞDEVİREN, N., GÜLER, S. (2022). Prevalence and Clinical Features of Idiopathic Parkinson’s Disease in Western Turkey. Nöropsikiyatri Arşivi, Cilt: 59 - Sayı: 2, 98–104. https://ajindex.com/articles/584585

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Wong SL, Gilmour H, Ramage-Morin PL. Parkinson’s disease: Prevalence, diagnosis and impact. Health Rep 2014
  2. 10–4. https://www150.statcan. gc.ca/n1/en/pub/82-003-x/2014011/article/14112-eng.pdf?st=XVPJ31ow 2. Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 2014
  3. 1583– 1590. [Crossref] 3. Osaki Y, Morita Y, Kuwahara T, Miyano I, Doi Y. Prevalence of Parkinson’s disease and atypical parkinsonian syndromes in a rural Japanese district. Acta Neurol Scand 2011
  4. 182–187. [Crossref] 4. Tandberg E, Larsen JP, Nessler EG, Riise T, Aarli JA. The epidemiology of Parkinson’s disease in the county of Rogaland, Norway. Mov Disord 1995
  5. 541–549. [Crossref] 5. Savica R, Grossardt BR, Bower JH, Ahlskog JE, Rocca WA. Incidence and pathology of synucleinopathies and tauopathies related to parkinsonism. JAMA Neurol 2013
  6. 859–866. [Crossref] 6. Nerius M, Fink A, Doblhammer G. Parkinson’s disease in Germany: prevalence and incidence based on health claims data. Acta Neurol Scand 2017
  7. 386–392. [Crossref] 7. Wermuth L, Bech S, Petersen MS, Joensen P, Weihe P, Grandjean P. Prevalence and incidence of Parkinson’s disease in The Faroe Islands. Acta Neurol Scand 2008
  8. 126–131. [Crossref] 8. Blin P, Dureau-Pournin C, Foubert-Samier A, Grolleau A, Corbillon E, Jove J ve ark. Parkinson’s disease incidence and prevalence assessment in France using the national healthcare insurance database. Eur J Neurol 2015
  9. 464– 471. [Crossref] 9. Durmus H, Gokalp MA, Hanagasi HA. Prevalence of Parkinson’s disease in Baskale, Turkey: a population based study. Neurol Sci 2015
  10. 411–413. [Crossref] 10. Özbek SE, Zarifoğlu M, Karlı N, Özçakır A, Yıldız D, Aslan D. A Population- Based Survey to Determine the Prevalence of Movement Disorders in Orhangazi District of Bursa, Turkey. Turk J Neurol 2009
  11. 109–118. https:// jag.journalagent.com/tjn/pdfs/TJN_15_3_109_118.pdf 11. Torun Ş, Uysal M, Gücüyener D, Özdemir G. Parkinson’s disease in Eskişehir, Turkey. Eur J Neurol 1995
  12. 44–45. 12. Singh J, Jain DC, Sharma RS, Verghese T. Evaluation of immunization coverage by lot quality assurance sampling compared with 30-cluster sampling in a primary health centre in India. Bull World Health Organ 1996
  13. 269–274. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2486926/ 13. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study o